CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,380,336 | +166.2% | 42,400 | +92.7% | 0.26% | +107.0% |
| Q4 2022 | $894,300 | -37.8% | 22,000 | 0.0% | 0.13% | -34.4% |
| Q3 2022 | $1,438,000 | +7.6% | 22,000 | 0.0% | 0.20% | -6.7% |
| Q2 2022 | $1,337,000 | -3.2% | 22,000 | 0.0% | 0.21% | +17.4% |
| Q1 2022 | $1,381,000 | -17.2% | 22,000 | 0.0% | 0.18% | +6.6% |
| Q4 2021 | $1,667,000 | -83.9% | 22,000 | -76.1% | 0.17% | -89.6% |
| Q3 2021 | $10,322,000 | -38.2% | 92,214 | -10.6% | 1.61% | -37.4% |
| Q2 2021 | $16,693,000 | +907.4% | 103,114 | +852.6% | 2.57% | +1072.1% |
| Q4 2020 | $1,657,000 | +94.3% | 10,825 | +6.1% | 0.22% | -51.5% |
| Q3 2020 | $853,000 | -32.5% | 10,200 | -40.7% | 0.45% | -37.3% |
| Q2 2020 | $1,264,000 | +81.6% | 17,200 | +4.9% | 0.72% | -11.0% |
| Q1 2020 | $696,000 | -48.7% | 16,400 | -26.5% | 0.81% | -38.2% |
| Q4 2019 | $1,358,000 | – | 22,300 | – | 1.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |